Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

2020517 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov identifier: NCT02231749.

No poverty

Published in: ESMO Open

Volume 5, Issue 6, pp. e001079-e001079

Field-Weighted Citation Impact: 45.57